/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.45%
Natural Gas
+1.40%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
EUR/USD
-0.45%
Natural Gas
+1.40%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Germany: Stable Government Needed to Address Shifts in US Policy and Raise Growth Outlook
about 3 hours ago
Federal Reserve Cuts Federal Funds Rate By 25 Bps
about 20 hours ago
BOE Trims Rates to 4.75%, Balances Easing with Inflation and Budget Uncertainty
1 day ago
German Exports Slide by 1.7% in September as Trump Tariffs Loom
about 11 hours ago
Crude Inventories Rise By 2.1 Million Barrels, Exceeding Analyst Expectations
2 days ago
US: Clear-cut Trump Victory Raises Medium-term Economic Risks Despite Reduction of Near-term Political Uncertainty
2 days ago
Silver (XAG) Forecast: No Boost from China’s Stimulus, Silver Weakens on Fed Caution
16 minutes ago
NASDAQ, Dow Jones and S&P 500 Weekly Forecast – US Indices Rally for the Week
23 minutes ago
EUR/USD, USD/JPY and AUD/USD Weekly Forecast – Mixed Week for the Forex Markets
32 minutes ago
Stocks Rallied: What’s Next for the Market?
about 1 hour ago
NASDAQ, Dow Jones and S&P 500 Forecast – US Indices See Sluggish Action on Friday
about 1 hour ago
EUR/USD, USD/JPY and AUD/USD Forecast – Friday Session Mixed for US Dollar
about 1 hour ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
RVNC
profile
Revance Therapeutics Inc
Follow
RVNC
(
Nasdaq - US
)
Open
3.96
-1.82 (-31.49%)
in
:
usd
•
As of: Nov 08, 2024 10:01
UTC -5
Open
4.25
High
4.34
Low
3.92
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Revance Therapeutics Inc
CEO
Mark J. Foley
Headquarters
1222 demonbreun street, suite 2000
nashville, tn 37203, united states
Auditor
PricewaterhouseCoopers LLP
Employees
597
Share Holders
155
Website
www.revance.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Revance Therapeutics Inc
Statistics
Valuation Measures
Market Capitalization
2
415.09M
Enterprise Value
781.66M
Enterprise Value/EBITDA
(ttm)
-3.94
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
N/A
Price to Sales
(ttm)
2.50
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
69.47%
Operating Margin
(ttm)
-84.75%
Profit Margin
(ttm)
-120.14%
Return on Equity
(ttm)
N/A
Return on Invested Capital
(ttm)
-99.65%
Return on Assets
(ttm)
-41.05%
Income Statement
Revenue
(ttm)
251.18M
Revenue Per Share
(ttm)
2.40
Gross Profit
(ttm)
174.36M
EBITDA
(ttm)
3
-198.49M
Net Income Avi to Common
(ttm)
-287.50M
Diluted EPS
(ttm)
-3.19
Share Statistics
Beta (5Y Monthly)
0.95
52-Week Change
-52.46%
S&P500 52-Week Change
36.44%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
104.82M
Dividend Yield
0.00%
Float
4
99.48M
%
Held by Insiders
5.10%
%
Held by Institutions
97.70%
Balance Sheet
Total Cash
(mrq)
232.52M
Total Cash Per Share
(mrq)
2.22
Total Debt
(mrq)
448.30M
Total Debt/Equity
(mrq)
-345.54%
Current Ratio
(mrq)
3.74%
Quick Ratio
(mrq)
3.01%
Book Value Per Share
(mrq)
-1.24
Cash Flow
Operating Cash Flow Per Share
(ytd)
-1.03
Free Cash Flow
(ytd)
-109.25M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker